You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

LYMPHAZURIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lymphazurin, and when can generic versions of Lymphazurin launch?

Lymphazurin is a drug marketed by Covidien and is included in one NDA.

The generic ingredient in LYMPHAZURIN is isosulfan blue. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isosulfan blue profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lymphazurin

A generic version of LYMPHAZURIN was approved as isosulfan blue by MYLAN INSTITUTIONAL on July 20th, 2010.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LYMPHAZURIN?
  • What are the global sales for LYMPHAZURIN?
  • What is Average Wholesale Price for LYMPHAZURIN?
Summary for LYMPHAZURIN
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 41
Clinical Trials: 10
Patent Applications: 282
What excipients (inactive ingredients) are in LYMPHAZURIN?LYMPHAZURIN excipients list
DailyMed Link:LYMPHAZURIN at DailyMed
Drug patent expirations by year for LYMPHAZURIN
Recent Clinical Trials for LYMPHAZURIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cardinal Health 414, LLCPhase 1
University of California, San DiegoPhase 1
Navidea BiopharmaceuticalsPhase 1

See all LYMPHAZURIN clinical trials

US Patents and Regulatory Information for LYMPHAZURIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covidien LYMPHAZURIN isosulfan blue SOLUTION;SUBCUTANEOUS 018310-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.